Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Laboratories has received tentative approval from the FDA to manufacture and market a generic version of Sanofi-Aventis' insomnia drug Ambien.
Subscribe to our email newsletter
Ranbaxy said that it plans to manufacture the zolpidem tartrate tablets in 5mg and 10mg strengths. The products will be manufactured at the company’s New Jersey Ohm Laboratories facility.
Total annual market sales for zolpidem tartrate tablets were $2.12 billion, according to Ranbaxy.
“This product will be launched following final approval from the FDA and presents yet another opportunity for Ranbaxy to expand its product portfolio by offering an affordable generic alternative,” said Jim Meehan, vice president of sales and marketing for Ranbaxy Pharmaceuticals in the US.